NewAmsterdam Pharma (NASDAQ:NAMS) Stock Price Up 5.8% - What's Next?

Key Points

• NewAmsterdam Pharma shares rose 5.8% to about $23.89, though trading volume was 37% below the average session volume.
• Analyst sentiment remains broadly positive, with a “Moderate Buy” consensus and an average price target of $49.73, despite ratings ranging from Sell to Strong Buy.
• The company reported a quarterly loss of $0.52 per share, missing estimates, while revenue exceeded expectations. Insiders have sold roughly 231,600 shares over the past 90 days, whereas institutional investors own nearly 90% of the stock.

Shares of NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS - Get Free Report) rose 5.8% on Monday. The stock traded as high as $23.74 and last traded at $23.8850. Approximately 708,318 shares were traded during trading, a decline of 37% from the average session volume of 1,118,843 shares. The stock had previously closed at $22.58.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on the stock. BMO Capital Markets assumed coverage on shares of NewAmsterdam Pharma in a research report on Monday, July 20th. They set an "outperform" rating and a $58.00 price objective for the company. Weiss Ratings reiterated a "sell (d-)" rating on shares of NewAmsterdam Pharma in a report on Friday, July 17th. Royal Bank Of Canada lowered their price objective on NewAmsterdam Pharma from $51.00 to $50.00 and set an "outperform" rating for the company in a research report on Thursday, August 6th. Jefferies Financial Group restated a "buy" rating and issued a $45.00 target price on shares of NewAmsterdam Pharma in a research report on Monday, July 20th. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $52.00 price target on shares of NewAmsterdam Pharma in a research note on Tuesday, September 8th. One research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat, NewAmsterdam Pharma has an average rating of "Moderate Buy" and a consensus price target of $49.73.

NewAmsterdam Pharma Price Performance

The business has a 50 day simple moving average of $26.25 and a 200 day simple moving average of $30.46. The company has a market capitalization of $2.83 billion, a price-to-earnings ratio of -11.03 and a beta of 0.09.

NewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) last issued its quarterly earnings data on Wednesday, August 5th. The company reported ($0.52) earnings per share for the quarter, missing analysts' consensus estimates of ($0.48) by ($0.04). NewAmsterdam Pharma had a negative net margin of 3,644.21% and a negative return on equity of 34.81%. The firm had revenue of $3.70 million during the quarter, compared to analyst estimates of $2.83 million. On average, equities research analysts predict that NewAmsterdam Pharma Company N.V. will post -1.82 EPS for the current year.

Insider Buying and Selling at NewAmsterdam Pharma

In other NewAmsterdam Pharma news, Director John W. Smither sold 1,600 shares of the firm's stock in a transaction that occurred on Friday, September 4th. The shares were sold at an average price of $25.32, for a total value of $40,512.00. Following the completion of the transaction, the director owned 8,760 shares of the company's stock, valued at $221,803.20. This trade represents a 15.44% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Also, CAO Louise Kooij sold 105,000 shares of the business's stock in a transaction on Monday, July 20th. The stock was sold at an average price of $30.34, for a total transaction of $3,185,700.00. Following the completion of the transaction, the chief accounting officer owned 24,353 shares of the company's stock, valued at approximately $738,870.02. This trade represents a 81.17% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders have sold 231,600 shares of company stock worth $6,589,962. 12.74% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of NAMS. Frazier Life Sciences Management L.P. grew its stake in NewAmsterdam Pharma by 6.8% during the 2nd quarter. Frazier Life Sciences Management L.P. now owns 18,088,902 shares of the company's stock worth $613,033,000 after purchasing an additional 1,145,128 shares in the last quarter. Capital World Investors boosted its stake in shares of NewAmsterdam Pharma by 1.6% in the 4th quarter. Capital World Investors now owns 9,984,000 shares of the company's stock valued at $350,239,000 after buying an additional 161,289 shares during the period. Maverick Capital Ltd. grew its position in shares of NewAmsterdam Pharma by 15.4% during the first quarter. Maverick Capital Ltd. now owns 2,186,402 shares of the company's stock worth $69,987,000 after buying an additional 292,176 shares in the last quarter. Castle Hook Partners LP acquired a new position in shares of NewAmsterdam Pharma during the fourth quarter worth about $38,062,000. Finally, First Turn Management LLC increased its stake in shares of NewAmsterdam Pharma by 24.6% during the fourth quarter. First Turn Management LLC now owns 893,473 shares of the company's stock worth $31,343,000 after buying an additional 176,502 shares during the period. 89.89% of the stock is currently owned by hedge funds and other institutional investors.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma Company N.V. is a clinical-stage biopharmaceutical company focused on developing therapies for cardiometabolic diseases, particularly conditions involving elevated cholesterol and residual cardiovascular risk. The company's lead product candidate is obicetrapib, an oral, low-dose cholesteryl ester transfer protein (CETP) inhibitor designed to reduce low-density lipoprotein cholesterol and improve other lipid parameters.

Obicetrapib has been evaluated in several clinical studies, including the Phase 3 BROADWAY trial, for patients whose cholesterol levels remain inadequately controlled despite the use of existing lipid-lowering treatments.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.